Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether interleukin-2, interferon-alpha in
combination with bevacizumab are effective in the treatment of metastatic renal cell
carcinoma (mRCC).